Janux Therapeutics doses first patient in JANX013 Phase 1 trial

September 14, 2026 8:01 AM

Janux Therapeutics (Nasdaq: JANX) announced that the first patient has been dosed in a Phase 1 clinical trial evaluating JANX013 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found